Get the Stockscreener App
25.16
2.25%
-0.58
Pacira Biosciences Inc stock is traded at $25.16, with a volume of 566.81K.
It is down -2.25% in the last 24 hours and up +10.16% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
See More
Previous Close:
$25.74
Open:
$26.02
24h Volume:
566.81K
Relative Volume:
0.73
Market Cap:
$1.16B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
17.35
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-1.10%
1M Performance:
+10.16%
6M Performance:
+81.66%
1Y Performance:
-15.29%
1-Day Range:
$25.09
$26.17
1-Week Range:
$25.09
$26.89
52-Week Range:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
813-553-6680
Address
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.16 | 1.16B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. LawsuitPCRX - ACCESS Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - PR Newswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel ... - The Bakersfield Californian
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX - GlobeNewswire Inc.
Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class ActionPCRX - Morningstar
Class Action Filed Against Pacira BioSciences, Inc. (PCRX)March 14, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - ACCESS Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Pacira to Report 2024 Financial Results on Thursday February 27, 2025 - GlobeNewswire
Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your RightsPCRX - PR Newswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. - GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire
Investors who lost money on Pacira BioSciences, Inc. (PCRX) - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel ... - The Bakersfield Californian
Lost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - GuruFocus.com
Yousif Capital Management LLC Has $340,000 Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Issues Positive Outlook for PCRX Earnings - MarketBeat
Zacks Research Issues Pessimistic Forecast for PCRX Earnings - MarketBeat
PCRX Shareholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - Markets Insider
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $22.78 Consensus Price Target from Analysts - MarketBeat
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $22.78 - Defense World
Shares Of Pacira BioSciences Inc (NASDAQ: PCRX): Are They Overvalued Compared To Others? - Stocks Register
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - StreetInsider.com
What is Zacks Research’s Estimate for PCRX FY2024 Earnings? - Defense World
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira - PR Newswire
Empowered Funds LLC Buys 11,149 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Pacira BioSciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - Morningstar
Q4 EPS Estimate for Pacira BioSciences Boosted by Analyst - Defense World
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - Marketscreener.com
The Gross Law Firm Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - Morningstar
Lawsuit Alert: Investors in shares of Pacira BioSciences, Inc. - openPR
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel - The Bakersfield Californian
A Guide To The Risks Of Investing In Pacira BioSciences Inc (PCRX) - Knox Daily
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 14, 2025 to Discuss Your RightsPCRX - PR Newswire
Shareholders that lost money on Pacira BioSciences, - GlobeNewswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Janney Montgomery Scott LLC - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira - GlobeNewswire
Pacira BioSciences Inc (PCRX) Shares Decline Despite Market Challenges - The News Heater
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - PR Newswire
PCRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Is Pacira BioSciences Inc (PCRX) a good investment opportunity? - US Post News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):